HOme-based SElf-testiNG - a Cluster Randomized Controlled Trial in Rural Lesotho (HOSENG)

NACompletedINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

September 9, 2019

Conditions
HIVHIV/AIDS
Interventions
DIAGNOSTIC_TEST

OraQuick

Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.

Trial Locations (2)

Unknown

District of Butha-Buthe, Butha-Buthe

District of Mokhotlong, Mokhotlong

All Listed Sponsors
collaborator

SolidarMed

OTHER

collaborator

Ministry of Health, Lesotho

OTHER_GOV

collaborator

University of Basel

OTHER

collaborator

University Hospital, Basel, Switzerland

OTHER

lead

Tracy Glass

OTHER

NCT03598686 - HOme-based SElf-testiNG - a Cluster Randomized Controlled Trial in Rural Lesotho (HOSENG) | Biotech Hunter | Biotech Hunter